Abdourahim Chamouine

Abdourahim Chamouine

Auto-generated profile, based on publicly available information

Abdourahim Chamouine

Pediatric Unit, Mamoudzou General Hospital, 1, Rue de l'Hopital, BP 4, 97600, Mamoudzou, Mayotte, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VBValentine Brousse
Valentine Brousse
CACécile Arnaud
Cécile Arnaud
ELEmmanuelle Lesprit
Emmanuelle Lesprit
BQBéatrice Quinet
Béatrice Quinet
MOMarie-Hélène Odièvre
Marie-Hélène Odièvre
ITIsabelle Thuret
Isabelle Thuret
This study’s objective was to assess, on a national scale, residual risks of death, major disease-related events, and quality of care during the first five years in children diagnosed at birth with sickle cell disease (SCD). Data were retrospectively collected from medical files of all children with SCD born between 2006–2010 in France. Out of 1792 eligible subjects, 1620 patients (71.8% SS or S/beta°-thalassemia -SB°-) had available follow-up data, across 69 centers. Overall probability of survival by five years was 98.9%, with 12/18 deaths related to SCD. Probability of overt stroke by five years in SS/SB° patients was 1.1%, while transcranial Doppler (TCD) was performed in 81% before three years of age. A total of 26 patients had meningitis/septicemia (pneumococcal in eight cases). Prophylactic penicillin was started at a median age of 2.2 months and 87% of children had received appropriate conjugate pneumococcal vaccination at one year. By five years, the probability of survival without SCD-related events was 10.7% for SS/SB° patients. In contrast, hydroxyurea was prescribed in 13.7% and bone marrow transplant performed in nine patients only. In this study, residual risks of severe complications were low, probably resulting from a good national TCD, vaccination, and healthcare system coverage. Nonetheless, burden of disease remained high, stressing the need for disease-modifying or curative therapy.

25 March 2015 in Hemoglobin
Verified
Journal Article
Closed access
MMMathias Muszlak
Mathias Muszlak
SPSerge Pissard
Serge Pissard
CBCatherine Badens
Catherine Badens
ACAbdourahim Chamouine
Abdourahim Chamouine
OMOlivier Maillard
Olivier Maillard
ITIsabelle Thuret
Isabelle Thuret
Sickle cell disease presents a great clinical variability that remains largely misunderstood. New disease protective genetic modifiers acting mainly through an increased Hb F level have recently been described. We studied relations between clinical and hematological phenotypes and known sickle cell disease genetic modifiers in patients from Mayotte Island, a remote French territory located in the Indian Ocean. Eighty-two children with sickle cell disease were enrolled; their median age was 5.9 years (range 1-18). Clinical and hematological features of sickle cell disease were retrospectively collected. Genetic studies included determination of β-globin genotypes [Hb SS, Hb S-β(0)-thalassemia (Hb S-β(0)-thal), Hb S-β(+)-thal], β(S)-globin locus haplotype, α-thalassemia (α-thal), and single nucleotide polymorphisms (SNPs) located in quantitative trait loci for Hb F expression (XmnI polymorphism, BCL11A rs4671393 and rs11886868, intergenic region of HBS1L-MYB rs28384513, rs4895441 and rs9399137). Univariate and multivariate analyses were conducted. Twenty-eight percent of the patients had Hb S-β-thal (eight different mutations in 21 patients), 55.0% had the -α(3.7) (rightward) deletion and 88.0% of the homozygous Hb SS patients were carrying a homozygous Bantu haplotype. In the multivariate model, the prognosis role of the SNP BCL11A rs4671393 was confirmed in the studied population showing a significant association with an elevated Hb F level and with a low hospitalization rate. The -α(3.7) deletion, XmnI polymorphism and intergenic region HBS1L-MYB SNPs were not significantly linked to any clinical criteria of severity. This report, the first to describe the main features of children with sickle cell disease on Mayotte Island, highlights the protective effect of the BCL11A polymorphism in this population.

20 June 2020 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
ACAbdourahim Chamouine
Abdourahim Chamouine
TSThoueiba Saandi
Thoueiba Saandi
MMMathias Muszlak
Mathias Muszlak
JLJuliette Larmaraud
Juliette Larmaraud
LLLaurent Lambrecht
Laurent Lambrecht
Narcisse ELENGANarcisse ELENGA
Narcisse ELENGA
Background: Understanding the genetics underlying the heritable subphenotypes of sickle cell anemia, specific to each population, would be prognostically useful and could inform personalized therapeutics.The objective of this study was to describe the genetic modulators of sickle cell disease in a cohort of pediatric patients followed up in Mayotte. Methods: This retrospective cohort study analyzed clinical and biological data, collected between January1st2007 and December 31st2017, in children younger than 18 years. Results: We included 185 children with 72% SS, 16% Sβ0-thalassemia and 12% Sβ + thalassemia. The average age was 9.5 years; 10% of patients were lost to follow up. The Bantu haplotype was associated with an increase in hospitalizations and transfusions. The alpha-thalassemic mutation was associated with a decrease of hemolysis biological parameters (anemia, reticulocytes), and a decrease of cerebral vasculopathy. The Single Nucleotide Polymorphisms BCL11A rs4671393, BCL11A rs11886868, BCL11A rs1427407 and HMIP rs9399137 were associated with the group of children with HbF > 10%. Patients with HbF > 10% presented a significant risk of early onset of cerebral vasculopathy. Conclusions: The most remarkable result of our study was the association of SNPs with clinically relevant phenotypic groups. BCL11A rs4671393, BCL11A rs11886868, BCL11A rs1427407 and HMIP rs9399137 were correlated with HbF > 10%, a group that has a higher risk of cerebral vasculopathy and should be oriented towards the hemolytic sub-phenotype.

13 August 2021 in Archives de Pédiatrie
Verified
Journal Article
Closed access
SHS. Haji
S. Haji
ZOZ. Ouchinsky
Z. Ouchinsky
BDB. Djoumoi
B. Djoumoi
TBT. Benoit-Cattin
T. Benoit-Cattin
ACA. Chamouine
A. Chamouine

24 November 2022 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
CTCorentin Tanné
Corentin Tanné
MMMarc Molho
Marc Molho
MDMounia Djoussouf
Mounia Djoussouf
ACAbdourahim Chamouine
Abdourahim Chamouine

12 February 2026 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
ABAurélie De Bruyne
Aurélie De Bruyne
AIApolline Imbard
Apolline Imbard
CRCharles‐Joris Roux
Charles‐Joris Roux
ACAbdourhahim Chamouine
Abdourhahim Chamouine
CSCamille Schwab
Camille Schwab
MSManuel Schiff
Manuel Schiff
Arginase 1 deficiency (ARG1D) is the least common urea cycle disorder. Neonatal onset is rarely described, and hyperammonemic coma is less common in patients with ARG1D compared to other urea cycle disorders. In recent years, we diagnosed a high number of ARG1D patients in Mayotte, an insular (Comoro Islands) department of France. This study aimed at retrospectively analyze and compare our patients' data with those diagnosed and followed in Paris. We present a series of 27 subjects included either in the Center Hospitalier de Mayotte (CHM), Mamoudzou, France ( n = 17), or in Hôpital Necker‐Enfants Malades (NEM), Paris, France ( n = 10). Median age at diagnosis ( n = 27) was 2 years (ranging from birth to 15 years). Patients diagnosed at CHM were generally older than those diagnosed at NEM, which may reflect a longer diagnostic delay in CHM. The main clinical features at diagnosis included hyperammonemic coma (with or without liver failure) and neurodevelopmental delay with spastic diplegia. Brain MRI could be either normal or showed severe lesions in patients with overt hyperammonemia at diagnosis. Eight different ARG1 variants were identified, including two variants (c.466‐2 A>G and c.766G>A) that were found exclusively in subjects originating from the Comoro Islands. Despite no significant differences in laboratory parameters, clinical outcomes remained better in NEM versus CHM possibly ascribable to a longer diagnostic delay in CHM. These findings revealed a new cluster of ARG1D associated with two severe variants in Mayotte, suggesting that this region could possibly benefit from targeted newborn screening for ARG1D due to its overrepresentation.